In the US, TAGRISSO (osimertinib systemic) is a member of the drug class EGFR inhibitors and is used to treat Non-Small Cell Lung Cancer.
Ingredient matches for TAGRISSO
Osimertinib mesylate (a derivative of Osimertinib) is reported as an ingredient of TAGRISSO in the following countries:
- United Kingdom
- United States
← International Drug Name Search
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.